Royalty Pharma plc (RPRX) NASDAQ
48.46
+0.56(+1.17%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
48.46
+0.56(+1.17%)
Currency In USD
Address
110 East 59th Street
New York City, NY 10022
United States of America (the)
Phone
212 883 0200
Sector
Healthcare
Industry
Biotechnology
Employees
75
First IPO Date
June 16, 2020
| Name | Title | Pay | Year Born |
| Pablo Gerardo Legorreta | Founder, Chairman of the Board & Chief Executive Officer | 0 | 1964 |
| Marshall Urist | Executive Vice President of Research & Investments | 1.26M | 1976 |
| Christopher Hite | Vice Chairman & Executive Vice President | 1.26M | 1967 |
| George Wingate Lloyd | Executive VP of Investments & Chief Legal Officer | 1.26M | 1960 |
| Terrance Coyne | Executive VP & CFO | 1.26M | N/A |
| James Folmar Reddoch | Executive Vice President of Investments & Chief Scientific Officer | 3.4M | 1971 |
| Arthur Richard McGivern | Executive Vice President of Investments & General Counsel | 0 | N/A |
| Ashwin Pai | Executive Vice President of Investments | 0 | N/A |
| Eric Cornelius Schneider | Senior VP & Chief Technology Officer | 0 | N/A |
| George Grofik | Senior Vice President and Head of Investor Relations & Communications | 0 | N/A |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.